CoChat
Sign Up
Cited by 118Cancer-related cognitive impairment studiesMenopause: Health Impacts and TreatmentsCancer survivorship and care

Cognitive Function and Reproductive Hormones in Adjuvant Therapy for Breast Cancer

Open access
Bender, Catherine M, Paraska, Karen K, Sereika, Susan M, Ryan, Christopher M, Berga, Sarah L·2001·Journal of Pain and Symptom Management
DOI 10.1016/s0885-3924(01)00268-8
Open this paper in CoChat — free accountOpen PDF

Abstract

Deterioration in cognitive function-particularly learning, memory, and attention-has been reported by women with breast cancer who receive adjuvant chemotherapy. Deficits in cognitive function reported by women with breast cancer are similar to those experienced by women as a consequence of natural or surgical menopause. The basis of these deteriorations may include reductions in reproductive hormone levels, particularly estrogens and progesterones, that occur as a result of adjuvant chemotherapy. This paper critically examines the literature related to the impact of adjuvant chemotherapy and reproductive hormone changes on cognitive function in women with breast cancer and suggests direction for future research in this area. The paper proposes a framework for investigation of the problem and discusses the challenges associated with the conduct of this research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0885-3924(01)00268-8

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A subpopulation of TAM-treated patients experience cognitive disturbances such as confusion, deterioration of verbal memory, and executive dysfunction (often called "TAM brain fog").

    “TAM, via unknown mechanisms, induces cognitive impairment in humans.”

    From Tamoxifen induces cellular stress in the nervous system by inhibiting cholesterol synthesis (2015) · cites this paper as [1]

    The review’s “Mechanisms of Changes in Cognitive Function with Adjuvant Chemotherapy” section (page unavailable) reports tamoxifen-related CNS toxicities, including confusion, and says their mechanism is unclear. It does not specifically attribute verbal-memory deterioration or executive dysfunction to tamoxifen; the cognitive-domain findings in the breast-cancer section concern women receiving chemotherapy, some of whom also received tamoxifen. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 18

  1. Dodd M. Cancer patients' knowledge of che- motherapy: assessment and informational interven- tions. Oncol Nurs Forum 1982;9:39-44.
  2. Cimprich B. Attentional fatigue following breast cancer surgery. Res Nursing Health 1992;15: 199-207.
  3. Cimprich B. Age and extent of surgery affect attention in women treated for breast cancer. Res Nursing and Health 1998;21:229-238.
  4. Mehta RR, Beattie CW, Das Gupta TK. Endo- crine profile in breast cancer patients receiving che- motherapy. Breast Cancer Res Treat 1992;20:125- 132.
  5. Bender CM, Yasko JM, Kirkwood JM, et al. Cog- nitive function and quality of life in patients with melanoma receiving alpha-interferon. Clin Nurs Res 2000;9:350-361.
  6. Kimmel E, Bender CM. Cognitive dysfunction and its relationship to fatigue in persons with refrac- tory ovarian cancer receiving taxol alone and taxol with G-CSF. Oncol Nurs Forum 1994;21:345.
  7. Schagen SB, van Dam FSAM, Muller MJ, et al. Cognitive deficits after postoperative adjuvant che- motherapy for breast carcinoma. Cancer 1999;85: 640-650.
  8. Kramer ED, Lewis D, Raney B. Neurologic complications in children with soft tissue and osseus sarcoma. Cancer 1989;64:2600-2603.
  9. Walker RW, Allen JC, Rosen G. Transient cere- bral dysfunction secondary to high-dose methotrex- ate. J Clin Oncol 1986;4:1845-1850.
  10. Nelson RW, Frank JT. Intrathecal methotrex- ate-induced neurotoxicities. Am J Hosp Pharm 1981;38:65-68.
  11. Kori SH, Marshall, J. Tamoxifen-induced en- cephalopathy. Neurology 1982;32:A72-A73.
  12. Pannuti F, Di Marco AR, Rossi AP, et al. Se- quential hormone-chemotherapy in metastatic breast cancer. Panminerva Medica 1981;23:93-95.
  13. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Es- trogen improves psychological function in asymp- tomatic postmenopausal women. Obstet Gyn 1991; 78:991-995.
  14. Paganini-Hill A, Henderson VW. Estrogen defi- ciency and risk of Alzheimer's disease. Amer J Epid 1994;140:256-261.
  15. Yaffe K, Sawaya G, Lieberburg I, Grady D. Es- trogen therapy in posttmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279:688-695.
  16. McEntee WJ, Crook TH. Age-associated mem- ory impairment: a role for catecholamines. Neurol 1990;40:526-529.
  17. Caraceni A, Gangeri L, Martini C, et al. Neuro- toxicity of interferon-␣ in melanoma therapy. Can- cer 1998;83:482-489.
  18. Diggle PJ, Liang K, Zeger SL. Analysis of longi- tudinal data. New York: Oxford University Press 1994.

Cited by

Sorted by citations

Related

Authors
Bender, C. M., Paraska, K. K., Sereika, S. M., Ryan, C. M., & Berga, S. L.
Affiliations
University of Pittsburgh (US)
Corresponding author
Bender, Catherine M
ORCID
Venue
Journal of Pain and Symptom Management
Publisher
Elsevier BV
Published
2001-05
Volume
21
Issue
5
Pages
407-424
ISSN
0885-3924 (ISSN-L)
DOI
10.1016/s0885-3924(01)00268-8
OpenAlex
W182334483
Cited by
118
References
119
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 9 · 2013: 9 · 2012: 8
FWCI
1.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Pain and Symptom Management (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
breast cancer, adjuvant chemotherapy, cognitive function, cognitive impairment, reproductive hormones, estrogen, progesterone, menopause, learning and memory, attention, chemotherapy side effects
MeSH terms
Antineoplastic Agents, Breast Neoplasms, Cognition Disorders, Female, Humans, Gonadal Steroid Hormones, Chemotherapy, Adjuvant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review